Enteral and Parenteral Treatment with Caffeine for Preterm Infants in the Delivery Room: A Randomised Trial.
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
02
10
2022
pubmed:
28
10
2022
medline:
6
1
2023
entrez:
27
10
2022
Statut:
ppublish
Résumé
Early treatment with caffeine in the delivery room (DR) has been proposed to decrease the need for mechanical ventilation (MV) by limiting episodes of apnoea and improving respiratory mechanics in preterm infants. Our aim was to verify the hypothesis that intravenous or enteral administration of caffeine can be performed in the preterm infant in the DR. Infants with 25 Nineteen patients were treated with intravenous caffeine and 19 with enteral caffeine. In all patients the procedure was successfully performed. Peak blood level of caffeine 60 ± 15 min after administration in the DR was found to be below the therapeutic range (5 µg/mL) in 25 % of samples and above the therapeutic range in 3%. Blood level of caffeine 60 ± 15 min before administration of the second dose was found to be below the therapeutic range in 18% of samples. Intravenous and enteral administration of caffeine can be performed in the DR without interfering with infants' postnatal assistance. Some patients did not reach the therapeutic range, raising the question of which dose is the most effective to prevent MV. ClinicalTrials.gov identifier NCT04044976; EudraCT number 2018-003626-91.
Sections du résumé
BACKGROUND
BACKGROUND
Early treatment with caffeine in the delivery room (DR) has been proposed to decrease the need for mechanical ventilation (MV) by limiting episodes of apnoea and improving respiratory mechanics in preterm infants. Our aim was to verify the hypothesis that intravenous or enteral administration of caffeine can be performed in the preterm infant in the DR.
METHODS
METHODS
Infants with 25
RESULTS
RESULTS
Nineteen patients were treated with intravenous caffeine and 19 with enteral caffeine. In all patients the procedure was successfully performed. Peak blood level of caffeine 60 ± 15 min after administration in the DR was found to be below the therapeutic range (5 µg/mL) in 25 % of samples and above the therapeutic range in 3%. Blood level of caffeine 60 ± 15 min before administration of the second dose was found to be below the therapeutic range in 18% of samples.
CONCLUSIONS
CONCLUSIONS
Intravenous and enteral administration of caffeine can be performed in the DR without interfering with infants' postnatal assistance. Some patients did not reach the therapeutic range, raising the question of which dose is the most effective to prevent MV.
CLINICAL TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier NCT04044976; EudraCT number 2018-003626-91.
Identifiants
pubmed: 36301511
doi: 10.1007/s40272-022-00541-y
pii: 10.1007/s40272-022-00541-y
pmc: PMC9810558
doi:
Substances chimiques
Caffeine
3G6A5W338E
Banques de données
ClinicalTrials.gov
['NCT04044976']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-86Informations de copyright
© 2022. The Author(s).
Références
Foglia EE, Jensen EA, Kirpalani H. Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants. J Perinatol. 2017;37:1171–9.
doi: 10.1038/jp.2017.74
Kribs A, HummLer H. Ancillary therapies to enhance success of non-invasive modes of respiratory support—approaches to delivery room use of surfactant and caffeine? Semin Fetal Neonatal Med. 2016;21:212–8.
doi: 10.1016/j.siny.2016.02.011
Wright CJ, Polin RA, Kirpalani H. Continuous positive airway pressure to prevent neonatal lung injury: how did we get here, and how do we improve? J Pediatr. 2016;173:17-24.e2.
doi: 10.1016/j.jpeds.2016.02.059
Katheria AC, Sauberan JB, Akotia D, et al. A pilot randomised controlled trial of early versus routine caffeine in extremely premature infants. Am J Perinatol. 2015;32:879–86.
doi: 10.1055/s-0034-1543981
Dekker J, Hooper SB, van Vonderen JJ, et al. Caffeine to improve breathing effort of preterm infants at birth: a randomized controlled trial. Pediatr Res. 2017;82:290–6.
doi: 10.1038/pr.2017.45
Dani C, Cecchi A, Remaschi G, Mercadante D, et al. Study protocol: treatment with caffeine of the very preterm infant in the delivery room: a feasibility study. BMJ Open. 2020;10: e040105.
doi: 10.1136/bmjopen-2020-040105
Freeman D, Saxton V, Holberton J. A weight-based formula for the estimation of gastric tube insertion length in newborns. Adv Neonatal Care. 2012;12:179–82.
doi: 10.1097/ANC.0b013e318256bb13
Long JY, Guo HL, He X, et al. caffeine for the pharmacological treatment of apnea of prematurity in the NICU: dose selection conundrum, therapeutic drug monitoring and genetic factors. Front Pharmacol. 2021;12: 681842.
doi: 10.3389/fphar.2021.681842
Patel P, Mulla H, Kairamkonda V, et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br J Clin Pharmacol. 2013;75:805–13.
doi: 10.1111/j.1365-2125.2012.04392.x
Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: neonatal resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care (reprint). Pediatrics. 2015;136:S196-218.
doi: 10.1542/peds.2015-3373G
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome—2019 update. Neonatology. 2019;115:432–50.
doi: 10.1159/000499361
Sandri F, Plavka R, Ancora G, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics. 2010;125:e1402–9.
doi: 10.1542/peds.2009-2131
Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353–60.
doi: 10.1542/peds.2005-0249
Papile LS, Burstein J, Burstein R, et al. Incidence and evolution of the sub-ependymal intraventricular hemorrhage: a study of infants weighing less than 1500 grams. J Pediatr. 1978;92:529–34.
doi: 10.1016/S0022-3476(78)80282-0
Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1–12.
doi: 10.1097/00000658-197801000-00001
Committee for the Classification of the Retinopathy of Prematurity. An international classification of infection or inflammation of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130–4.
doi: 10.1001/archopht.1984.01040030908011
Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr. 1979;94:663–8.
doi: 10.1016/S0022-3476(79)80047-5
Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24:93–8.
doi: 10.1007/BF00613933
Brattström P, Russo C, Ley D, et al. High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis. Acta Paediatr. 2019;108:401–10.
doi: 10.1111/apa.14586
Aranda JV, Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatol. 1979;6:87–108.
doi: 10.1016/S0095-5108(18)31165-5
Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61:628–40.
doi: 10.1016/S0009-9236(97)90097-7